Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease

N K Sabharwal, A Lahiri

Nuclear cardiology is an evolving specialty that has recently benefited from technological and radiopharmaceutical advances. As a result there has been an increase in the accuracy of myocardial perfusion imaging (MPI) with gated single photon emission computed tomography (SPECT) for assessing the diagnosis and prognosis of coronary artery disease. Moreover, ECG gated SPECT allows the simultaneous assessment of both myocardial perfusion and left ventricular function, which provides additional prognostic value. With increasing concern over early detection of coronary artery disease and its effective treatment, myocardial perfusion imaging is ideally placed to provide a full “one stop” functional assessment for any patient, irrespective of their exercise capacity. This applies not only to patients with chest pain but also to those with myocardial infarction, revascularisation, and heart failure, and those being assessed for non-cardiac surgery. The focus of this review is the use of myocardial perfusion imaging in risk stratification for coronary artery disease.

The classical hallmark of myocardial ischaemia has been the presence of transient ST segment depression on exercise. The pre-test likelihood of coronary artery disease dictates the sensitivity and specificity of the stress ECG; thus in the presence of a low or intermediate pre-test likelihood of coronary disease the exercise ECG has poor diagnostic accuracy.1,2 In many health care systems, risk stratification of patients with chest pain syndromes is attempted using clinical and ECG evaluation and acute markers of myocardial injury. These are often followed by an exercise ECG if the resting ECG and troponin measurements are unremarkable. For many patients a stress ECG has poor sensitivity and specificity and is therefore unlikely to be the method of ideal choice.3 Functional myocardial perfusion imaging (MPI), which provides evidence by directly measuring “total ischaemic burden”, is clearly the method of choice in lower and intermediate risk patients.4 Worldwide, the uptake of myocardial perfusion is expanding, with increasing interest in the use of MPI as a gatekeeper to coronary angiography. In this review we focus on examining the diagnostic and prognostic value of state of the art myocardial perfusion imaging.

It has taken 25 years to establish the clinical role of MPI using single photon emission computed tomography (SPECT). MPI agents are potential myocardial flow tracers; thus they identify abnormal flow early in the ischaemic cascade, before wall motion abnormality or ECG changes become apparent. The advent of new radioisotopes (technetium-99m agents), advanced dual and triple headed SPECT gamma cameras, diverse pharmacological “stress” agents, newer computer software, and ECG gated SPECT have all come together to make MPI a versatile clinical tool. No less important was the formation of the American Society of Nuclear Cardiology (ASNC) in 1994, and the ensuing requirement for cardiologists in the USA to obtain a licence to carry out and read scans. Approximately 5.64 million myocardial perfusion scans were done in the USA in 2001 (Arlington Medical Resources, 2001).

A commonly used alternative to MPI is the stress echocardiogram. This technique relies on the detection of stress induced wall motion abnormalities. The overall sensitivity is lower than MPI but with a slightly higher specificity. The prognostic value of a normal scan is comparable to that of MPI4; however, the technique relies heavily on operator experience, is blighted by poor acoustic windows, and there is a lack of quantitation.

ISOTOPES

Though thallium-201 was the first radionuclide to be widely used in clinical practice, it was the advent of technetium-99m sestamibi and tomographic imaging (SPECT) with quantitative analysis that provided the thrust for further development. Technetium-99m agents are also better suited for imaging with modern gamma cameras. Table 1 shows the agents currently in use.

STRESS PROTOCOLS

There is a large body of diagnostic and prognostic data on myocardial perfusion imaging. The data are based on different agents, cameras, stress

See end of article for authors’ affiliations

Correspondence to: Dr Avijit Lahiri, Department of Cardiac Research, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ, UK, nph@cardiac-research.org

Accepted 19 May 2003

Abbreviations: ASNC, American Society of Nuclear Cardiology; CHRISTMAS, carvedilol hibernation reversible ischaemia trial: marker of success; EMPIRE, economics of myocardial perfusion imaging in Europe; END, economics of noninvasive diagnosis; FDG, fluorodeoxyglucose; MPI, myocardial perfusion imaging; PET, positron emission tomography; SPECT, single photon emission computed tomography; SSS, summed stress score
agents, and acquisition protocols. The resultant confusion has not furthered the cause of nuclear cardiology. Here we attempt to rationalise some of the methods used in the acquisition of myocardial perfusion images.

Patients are subjected to “stress” image acquisition after achieving peak stress in the conventional way (treadmill or bicycle), and they also undergo “rest” or “redistribution” image acquisition at a different time. The versatility of radionuclides allows different protocols to be used for evaluating myocardial viability, detecting reversible ischaemia, and simultaneously assessing perfusion and left ventricular function by gated SPECT.

Patients unable to achieve adequate treadmill stress undergo vasodilator stress with intravenous dipyridamole or adenosine. These vasodilator pharmacological stress studies are often combined with submaximal exercise which improves myocardial uptake, reduces liver and gut uptake of technetium-99m agents, and diminishes vasodilator side effects. This observation by Pennell and colleagues has now become widely used for both adenosine and dipyridamole protocols. Dobutamine is a commonly used alternative to adenosine in patients with obstructive airways disease. The use of arbutamine has also been reported but its availability is restricted. New cardiospecific adenosine (A₂A receptor) agonists are undergoing clinical evaluation and promise the specific induction of coronary hyperaemia.

**RISK STRATIFICATION**

The normal perfusion scan

The prognostic value of thallium-201 is well established. A normal stress thallium-201 study has independent prognostic value. A six year follow up study of normal thallium-201 perfusion studies (on 1137 patients) showed that the cardiac event rate (non-fatal myocardial infarction or cardiac death) was only 0.88%. Recent studies have shown that, in the presence of a normal stress myocardial perfusion scan, exercise ECG had no added prognostic value.

Technetium-99m sestamibi has been found to have a similar prognostic value. One of the problems with functional imaging has been poor specificity. The improvement in specificity with SPECT imaging is established, but technetium-99m sestamibi has clear advantages over thallium-201 SPECT, where gated sestamibi is better than non-gated. Table 2 shows the clear advantage of functional perfusion imaging—a normal scan is associated with a very low cardiac event rate. In 473 patients with chest pain, of whom 65% had an abnormal ST segment response to exercise, Soman and colleagues clearly showed the superior prognostic power of technetium-99m sestamibi, where normal scans were associated with an annual mortality of 0.2%. Similarly a recent review of 14 trials including over 12 000 patients with stable chest pain confirmed that normal technetium 99m-sestamibi SPECT is associated with a hard cardiac event rate of 0.6% per year.

**The abnormal perfusion scan**

As the myocardial perfusion scan represents global left ventricular perfusion, the size, severity, and reversibility of the defect implies the extent of risk, or the “total ischaemic burden”. Similarly, a calculation of the number of segments involved on a multislice tomographic evaluation of the SPECT study can be used to calculate both the extent and severity of the ischaemic myocardium. Using sequential short axis slices, a polar map can be evaluated either visually or quantitatively to assess the total ischaemic burden. Figures 1 and 2 show a myocardial perfusion study from a patient with significant disease of the left anterior descending coronary artery. These polar and three dimensional quantitative images demonstrate the value of SPECT in predicting the extent, severity, and reversibility of the defect.

### Table 1

Comparison of different radionuclide agents currently in routine clinical use for myocardial perfusion imaging

<table>
<thead>
<tr>
<th>Radionuclide</th>
<th>Half life</th>
<th>Activity administered</th>
<th>Effective dose</th>
<th>Mechanism of myocardial uptake</th>
<th>Redistribution</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>²⁰¹⁵Tl</td>
<td>72 hours</td>
<td>60–80 MBq</td>
<td>15–20 mSv</td>
<td>ATPase-K⁺ myocyte cell membrane integrity required</td>
<td>Redistributes</td>
<td>Poor quality images; difficult to gate. Prognostic data available, redistribution advantageous for viability detection.</td>
</tr>
<tr>
<td>⁹⁹ᵐTc-sestamibi</td>
<td>6 hours</td>
<td>800 MBq</td>
<td>8 mSv</td>
<td>Myocyte mitochondria</td>
<td>Minimal</td>
<td>Versatile agent; increasing use; viability detection validated against ²⁰¹⁵Tl, dobutamine stress echocardiography, and PET.</td>
</tr>
<tr>
<td>⁹⁹ᵐTc-tetrofosmin</td>
<td>6 hours</td>
<td>800 MBq</td>
<td>8 mSv</td>
<td>Not known</td>
<td>Nil</td>
<td>Poorer extraction with vasodilator stress; underestimates ischaemic burden; improved extracardiac clearance suggested.</td>
</tr>
</tbody>
</table>

MSS, megabequerel; mSv, millisievert; PET, positron emission tomography.

### Table 2

The value of a normal myocardial perfusion scan

<table>
<thead>
<tr>
<th>Author</th>
<th>Radionuclide</th>
<th>Stress</th>
<th>Number of patients</th>
<th>Follow up (mean (SD))</th>
<th>Cardiac event rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wackers 1985²⁵</td>
<td>Tl-201</td>
<td>Exercice</td>
<td>344</td>
<td>22 (3) months</td>
<td>1</td>
</tr>
<tr>
<td>Wahl 1985³⁶</td>
<td>Tl-201</td>
<td>Exercice</td>
<td>455</td>
<td>14 months</td>
<td>0.8</td>
</tr>
<tr>
<td>Steinberg 1993³⁷</td>
<td>Tl-201</td>
<td>Exercice</td>
<td>309</td>
<td>10.3 years</td>
<td>1</td>
</tr>
<tr>
<td>Brown 1994⁴⁴</td>
<td>MIBI</td>
<td>Exercise or dipyridamole</td>
<td>234</td>
<td>10 (3) months</td>
<td>0.5</td>
</tr>
<tr>
<td>Stratmann 1694⁴⁴</td>
<td>MIBI</td>
<td>Exercice</td>
<td>205</td>
<td>13 (5) months</td>
<td>0.5</td>
</tr>
<tr>
<td>Raiker 1994⁴⁴</td>
<td>MIBI</td>
<td>Exercice</td>
<td>208</td>
<td>13.5 (2.0) months</td>
<td>0.5</td>
</tr>
<tr>
<td>Heil 1995⁴⁳</td>
<td>MIBI</td>
<td>Dipyridamole</td>
<td>216</td>
<td>12.8 (6.8) months</td>
<td>1.4</td>
</tr>
<tr>
<td>Hochamowitz 1996⁴⁳</td>
<td>MIBI/Tl-201</td>
<td>Exercice</td>
<td>1623</td>
<td>566 (142) days</td>
<td>0.3</td>
</tr>
<tr>
<td>Hochamowitz 1997⁴⁴</td>
<td>MIBI/Tl-201</td>
<td>Adenosine</td>
<td>445</td>
<td>27.5 (9.1) months</td>
<td>1.6</td>
</tr>
<tr>
<td>Soman 1999⁴⁴</td>
<td>MIBI</td>
<td>Exercice</td>
<td>473</td>
<td>30 (16) months</td>
<td>0.2</td>
</tr>
<tr>
<td>Groutas 2000⁴⁴</td>
<td>TETRO/Tl-201</td>
<td>Exercise / adenosine-exercise</td>
<td>246</td>
<td>25 (3) months</td>
<td>0.4</td>
</tr>
</tbody>
</table>

Hard cardiac event rate with various radionuclide agents and stressors.
MIBI, technetium-99m sestamibi; TETRO, technetium-99m tetrofosmin.
and reversibility of the perfusion defect—that is, the total ischaemic burden.

Though semiquantitative techniques work well, the ASNC guidelines are helpful for most departments. These use the short axis slices to evaluate the uptake in four broad quadrants (anterior, septal, inferior, and lateral). The left ventricle is further divided into apical, mid, and basal segments. The apex is assessed with the vertical long axis slice. The slices are divided into 17-20 segments. The uptake is scored in five grades: normal, mild, moderate, severe, or absent uptake. These techniques help standardisation between individuals and centres. Recently a consensus statement has been produced to bring together MPI, echocardiography, and other imaging modes.\(^\text{19}\)

Well validated commercial quantitative programs are available on most gamma camera systems. The two most

---

**Figure 1** A 63 year old women with a previous anterior myocardial infarct presented with symptoms of dyspnoea and underwent a two day rest-stress technetium-99m sestamibi SPECT. The rest scan shows a small infarct in the antero-septal zone, but the stress scan shows reversible ischaemia with associated left ventricular dysfunction. This study indicates underlying viability and severe ischaemia and therefore represents a prognostically high risk study. A polar map or "bulls eye" is also shown. Blackout on the stress scan signifies total defect (infarct and ischaemia), while the white areas represent the amount of reversible ischaemia. EDV, end diastolic volume; ESV, end systolic volume; LVEF, left ventricular ejection fraction.

**Figure 2** Three dimensional images from the same patient as in fig 1, with a proximal stenosis of the left anterior descending coronary artery. These quantitative images represent the total ischaemic burden. A generic coronary tree has been overlaid in red. Images from Emory Cardiac Toolbox.\(^\text{21}\)
commonly used are QPS/QGS\textsuperscript{10} and the Emory Cardiac Toolbox (ECTb).\textsuperscript{21} Both provide a quantitative estimate of the total ischaemic burden and left ventricular function. They employ complex algorithms and modelling, rather than relying on simple count based programs. Though the programs generally agree, a recent study has shown some inherent variation.\textsuperscript{22} For perfusion studies these programs employ a “normal” database, and therefore perfusion values falling outside the confidence limits are highlighted and the severity of the defect is computed (figs 1 and 2).

A representative method of scoring the total ischaemic burden is to calculate the “summed stress score” or SSS, using the method developed at Cedars-Sinai Hospital (Los Angeles, California, USA).\textsuperscript{13} In large studies (over 20 000 patients) the SSS predicted patient outcome. A normal summed stress score (10-3) was associated with a mortality of less than 1%, whereas an increasing SSS predicted higher cardiac mortality.\textsuperscript{15}

Hachamovitch and colleagues evaluated the effects of medical treatment and revascularisation on mortality in patients stratified by the summed stress score.\textsuperscript{14} In lower risk scans (mildly abnormal; SSS 4-8), mortality was similar in both groups; thus there was no survival advantage for revascularisation. However, as the size of the defect increased (SSS > 9) so the advantage with revascularisation showed an increased survival benefit (fig 3). This has important implications for the treatment provided and the costs associated with it.

How do the exercise ECG and functional imaging compare in current medical practice? The Duke treadmill score is a validated scoring system for identifying risk after a standard Bruce protocol ECG treadmill test.\textsuperscript{23} This score relies on exercise time, ST segment changes, and anginal symptoms. A high grade Duke treadmill score was considered to be associated with a good outcome, but it was originally not clear whether perfusion imaging would have any added value when the treadmill score was high. MPI and exercise ECGs were done in 2203 patients who were stratified by low, intermediate, and high likelihood of significant coronary artery disease using history, examination, exercise ECG, and Duke treadmill score. MPI provided additional incremental prognostic value irrespective of the Duke treadmill score result (fig 4).\textsuperscript{15}

Other factors identified with MPI that are associated with a worse long term prognosis are evidence of multiple defects, left ventricular chamber dilatation post-exercise, and increased lung uptake with thallium-201.

These quantitative methods are also effective in a clinical trial where technetium-99m sestamibi was compared with technetium-99m tetrofosmin.\textsuperscript{26} This study using total ischaemic burden calculated by quantitative methods showed that tetrofosmin underestimated the extent of ischaemia in patients with known coronary artery disease. This may reflect the lower myocardial extraction fraction of technetium-99m tetrofosmin and has obvious clinical implications.

**GATED SPECT: SIMULTANEOUS MEASUREMENT OF MYOCARDIAL PERFUSION AND FUNCTION**

Gated SPECT has made a fundamental change in perfusion imaging by allowing clearer identification of attenuation artefacts (breast and diaphragm), cine visualisation of left ventricular wall thickening (flow/function relation), and accurate estimation of left ventricular ejection fraction and left ventricular volumes. The high photon flux and lack of redistribution of technetium-99m sestamibi clearly has an advantage over thallium-201. Owing to the higher count rate with technetium-99m agents there has been a considerable improvement in spatial and temporal resolution, thus allowing improved sensitivity and specificity for technetium-99m sestamibi\textsuperscript{27} or tetrofosmin\textsuperscript{28} over thallium-201.

Taillefer and colleagues compared the specificity of thallium-201, technetium-99m sestamibi, and ECG gated technetium-99m sestamibi SPECT in women.\textsuperscript{29} The specificity for thallium-201 SPECT was 67.2%, technetium-99m sestamibi SPECT 84.4%, and ECG gated technetium-99m sestamibi SPECT 92.2%. Others have confirmed the value of gated SPECT in decreasing the number of non-diagnostic studies.\textsuperscript{30}

In a recent study of patients with acute chest pain and non-ST-segment elevation, Swinburn and colleagues found that gated sestamibi SPECT abnormalities were highly indicative of a poor outcome when compared with markers of necrosis and inflammation.\textsuperscript{31}

**Post-exercise “stunning”**

Recent observations have shown significant left ventricular chamber dilatation or wall thickening abnormality following delayed post-exercise imaging with thallium-201, or in particular, technetium-99m sestamibi SPECT studies, 30-90 minutes after cessation of exercise.\textsuperscript{32-35} This phenomenon is thought to reflect post-ischaemic stunning or extensive subendocardial ischaemia. As technetium-99m sestamibi acts as a “microsphere”, the perfusion is “frozen” at the time of injection, but wall thickening changes reflect real time events at the time of imaging rather than at injection.

A seminal study by Sharir and colleagues has shown the value of assessing simultaneous perfusion and function from post-stress gated SPECT using the QGS program (fig 5).\textsuperscript{36} Addition of end systolic volume (ESV > 70 ml) to left ventricular ejection fraction (LVEF < 45%) clearly improved

---

**Figure 3** Rates of cardiac death per year as a function of scan result and type of treatment. Black bars represent patients undergoing medical treatment after SPECT; white bars represent patients undergoing revascularisation after SPECT. *p < 0.01 v patients undergoing revascularisation early after SPECT; **p < 0.001 within patients undergoing revascularisation early after SPECT.\textsuperscript{24}

**Figure 4** A multivariate Cox proportional hazards model for incremental prognostic value between clinical history, examination, exercise ECG, and nuclear imaging.\textsuperscript{15} ETT, exercise ECG; MPI, myocardial perfusion imaging.
Myocardial perfusion imaging in coronary artery disease

Diagnosis of coronary artery disease. Recent studies by Senior et al have shown that nitrate enhanced technetium-99m sestamibi SPECT is similar to dobutamine echocardiography (which reveals contractile reserve) and also to thallium-201 for determining myocardial viability. Siebelink et al also found that technetium-99m sestamibi SPECT was similar to FDG-PET imaging for detecting viability.

Recently studies by Senior et al and Kitsiou et al have demonstrated that painless myocardial ischaemia is a common finding of ischaemic cardiomyopathy. Its presence predicts viable myocardium and greater recovery of function after revascularisation. Thus, as ischaemia probably plays an important role in the genesis of repeated stunning or hibernation and therefore in further deterioration of left ventricular function, it was hypothesised that carvedilol, with its multiple actions, might improve hibernating myocardium (the CHRISTMAS trial: carvedilol hibernation reversible ischaemia trial: marker of success). This study has recently been reported and shows that both reversible ischaemia and myocardial viability are common features of ischaemic cardiomyopathy and heart failure. Carvedilol improved left ventricular function in both groups (with or without hibernation); however, it had a greater impact on patients with reversible ischaemia. The HEART-UK trial will set out to evaluate whether patients with myocardial viability have a better outcome after revascularisation than with maximum medical treatment.

Patients with severely impaired left ventricular systolic function and viability have a poor prognosis. The restoration of function either by revascularisation or by pharmacological means improves outcome. The ability to select patients with a standard SPECT protocol is obviously beneficial as this has prognostic and economic implications.

COST ECONOMICS

In the new climate of cost containment there has been some attempt to estimate the economic cost associated with MPI. The END (economics of noninvasive diagnosis) study compared direct cardiac catheterisation with MPI followed by selective cardiac catheterisation to diagnose coronary artery disease in specialist cardiology centres in the USA. None of the patients underwent risk stratification with the standard exercise ECG. Diagnostic and follow up costs were lower when a strategy employing MPI before selective cardiac catheterisation was used. The cardiac deaths and non-fatal myocardial infarction rates were slightly lower in the MPI arm than in the direct catheterisation arm, at 2.8% and 2.8% vs 3.3% and 3.0%, respectively (p = ns) (table 3). The EMPIRE (economics of myocardial perfusion imaging in Europe) study compared 396 patient records from eight hospitals in four European countries. Retrospective analysis on suitable patients was done to compare four different strategies used to diagnose coronary artery disease. The results suggested that a
REFERENCES


Improved detection of protruding apical thrombus with contrast echocardiography

A 68 year old man with a history of anterior myocardial infarction, congestive heart failure, and hypertension was referred for transthoracic echocardiography to evaluate left ventricular function. Tissue harmonic imaging of the apical four chamber view revealed inadequate endocardial definition of all myocardial segments, including the apex (below left). Therefore, images were repeated during intravenous octafluoropropane (Optison) injection. A 2 cm diameter protruding thrombus was visualised as a non-enhanced, spherical structure at the left ventricular apex (below right, arrowheads indicate protruding thrombus). This case illustrates the utility of contrast echocardiography to improve detection of apical thrombus in patients who have inadequate images from routine echocardiographic examination.

P Rerkpattanapipat
C Brown
D W Kitzman
prerkpat@wfubmc.edu
Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease

N K Sabharwal and A Lahiri

Heart 2003 89: 1291-1297
doi: 10.1136/heart.89.11.1291

Updated information and services can be found at:
http://heart.bmj.com/content/89/11/1291

These include:

References
This article cites 56 articles, 17 of which you can access for free at:
http://heart.bmj.com/content/89/11/1291#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/